Dxcover

Dxcover Limited is a clinical-stage company based in Glasgow, UK, founded in 2016. Specializing in early cancer detection, Dxcover utilizes innovative liquid biopsy technology combined with artificial intelligence. The company, originally named ClinSpec Diagnostics Limited, rebranded in 2021 after spinning out from the University of Strathclyde. Dxcover has developed the Dxcover Platform, which employs infrared spectroscopy and AI algorithms to analyze blood samples for early-stage cancers, including brain, colorectal, lung, pancreatic, ovarian, and kidney cancers. This platform detects biological signals that traditional methods may miss, allowing for rapid and accurate diagnosis without the need for specialized sample preparation. The company’s proprietary methods, such as 'Drop, Dry, Detect' and the Panoramic platform, enable the identification of cancer signatures in serum samples within minutes. With a mission to democratize cancer care, Dxcover aims to improve survival rates and quality of life by targeting high-risk populations. The company serves markets in the US, UK, and EU, focusing on providing fast, cost-effective diagnostic solutions. Dxcover is recognized for its pioneering work in oncology diagnostics and is expanding its operations internationally.

• Employees 30
• Founded 2016
• Annual Revenue $2000000
• Total Funding $25592403